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ABSTRACT
Inhibition of poly(ADP-ribose) polymerase (PARP) is a promising therapeutic 
strategy for BRCA1 deficient cancers, however, the development of drug resistance 
limits clinical efficacy. Previously we found that the BRCA1-AKT1 pathway contributes 
to tumorigenesis and that the AKT1/mTOR is a novel therapeutic target for BRCA1-
deficient cancers. Here, we report that phosphorylation of ribosomal protein S6, a 
mTOR downstream effector, is greatly increased in BRCA1 deficient cells resistant 
to PARP inhibition. Phosphorylation of S6 is associated with DNA damage and repair 
signaling during PARP inhibitor treatment. In BRCA1 deficient cells, expression of S6 
lacking all five phosphorylatable sites renders the cells sensitive to PARP inhibitor and 
increases DNA damage signals. In addition, the S6 mutations reduce tumor formation 
induced by Brca1-deficiency in mice. Inhibition of S6 phosphorylation by rapamycin 
restores PARP sensitivity to resistant cells. Combined treatment with rapamycin 
and PARP inhibitor effectively suppresses BRCA1-deficient tumor growth in mice. 
These results provide evidence for a novel mechanism by which BRCA1 deficient 
cancers acquire drug resistance and suggest a new therapeutic strategy to circumvent 
resistance. 
INTRODUCTION
The breast cancer susceptibility gene (BRCA1) is 
commonly found to be mutated in hereditary breast and 
ovarian cancers. In addition, BRCA1 protein expression 
is frequently reduced or is absent in sporadic cases, 
suggesting that it influences both hereditary and sporadic 
mammary tumorigenesis [1;2]. The BRCA1 protein 
contains C-terminal tandem BRCT domains that are 
phosphoprotein binding motifs, which are important for 
the tumor-suppressor and DNA repair function of BRCA1 
[3-5]. Clinically relevant missense mutations identified at 
the C-terminus of BRCA1 abolish the structure of BRCT. 
Most BRCA1 mutations result in truncated BRCA1 gene 
products that lack one or both C-terminal BRCT domains 
[6;7].
BRCA1-deficient cells have compromised DNA 
repair and are sensitive to poly(ADP-ribose) polymerase 
(PARP) inhibitors [8-10]. Loss or dysfunction of 
BRCA1 gene causes a deficiency in the homologous 
recombination (HR) repair and RAD51 focus 
formation, which contributes to genomic instability 
and tumorigenesis [11;12]. PARP inhibition is synthetic 
lethal with defective DNA repair via HR and, phase 1 
as well as phase 2 clinical trials have shown that PARP 
inhibitors have effective anti-tumor activity for BRCA-
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associated cancers [13;14]. Despite an initial response, 
chemo-resistance development eventually limits clinical 
efficacy [15-18]. The resistant mechanism is unclear, as 
data from fundamental and preclinical research indicates 
multiple mechanisms including genetic reversion of 
BRCA mutations, hypomorphic activity of mutant 
BRCA1 alleles, upregulation of drug efflux pumps and 
rewiring of the DNA damage response [19;20]. We 
previously demonstrated that the AKT/mTOR oncogenic 
pathway contributes to BRCA1-deficient tumorigenesis 
and defective DNA repair [21-23]. Here, we identify a 
novel mechanism for acquired PARP inhibitor resistance 
by demonstrating that phosphorylation of ribosomal 
protein S6, a downstream effector of the mTOR pathway, 
mediates PARP inhibitor resistance through attenuating 
the DNA damage response and restoring defective HR in 
BRCA1-deficient cancer cells. 
RESULTS
Increased phosphorylation of ribosomal protein 
S6 in BRCA1-deficient cancer cells is associated 
with resistance to a PARP inhibitor
To examine the role of ribosomal protein S6 in 
PARP inhibitor resistance, we used a PARP inhibitor 
olaparib to treat HCC1937 breast cancer cell line. This cell 
line is hemizygous for the BRCA1 mutant allele 5382insC 
and therefore expresses a BRCA1 protein lacking the 
COOH-terminal BRCT repeats. The mutation eliminates 
the activity of BRCA1 in the repair of DNA damage and 
maintenance of genomic stability and is associated with 
an increased risk of cancer. Treatment with olaparib 
for up to 5 days did not change ribosomal protein S6 
phosphorylation in HCC1937 cells (Fig. 1A), however, 
Fig. 1: S6 phosphorylation is increased in BRCA1 deficient cells with long time olaparib treatment. A. HCC1937 cells 
(BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western 
blotting with the indicated antibodies. B. Lysates were prepared from that stably expressed BRCA1 or vector only (+v) with or without 10 
nM olaparib treatment and analyzed by Western blotting with the indicated antibodies. C. Lysates from Brca1+/+ or Brca1tr/tr MEFs with 
or without 10 nM olaparib treatment were analyzed by Western blot with the indicated antibodies. D. HCC1937 clones OR1 to OR3 were 
significantly more resistant to olaparib than parental cells. Colony formation assay was performed (n=3. Mean±SEM of colonies formed 
relative to DMSO-treated cells). E. Lysates from HCC1937 parental cells and three olaparib resistant clones (OR1 to OR3) were analyzed 
by Western blot with the indicated antibodies. The cells were treated with 10 nM olaparib for three days.
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after two weeks of treatment S6 phosphorylation strongly 
increased. Expression of wild-type BRCA1 in HCC1937 
cells reduced the basal levels of S6 phosphorylation, 
consistent with our previous reports [22;23] (Fig. 1B). In 
addition, expression of BRCA1 suppressed the increase in 
S6 phosphorylation induced by olaparib treatment of two 
weeks. Furthermore, MEFs expressing a truncated Brca1 
allele (Brca1tr/tr) [5;22] showed higher S6 phosphorylation 
level two weeks after olaparib treatment (Fig. 1C), 
while Brca1+/+ MEFs did not. A similar phenomenon 
was observed in another BRCA1-mutant cell line 
SUM149 that S6 phosphorylation level increased after 
two week treatment with olaparib, but did not change in 
BRCA1 proficient cell lines MCF7 and MDA-MB-231 
(Supplemental Fig. 1 and data not shown). These results 
suggest that BRCA1 deficiency and S6 phosphorylation 
are involved in PARP inhibitor resistance. 
To verify PARP inhibitor resistance, we cultured 
HCC1937 in the presence of olaparib and obtained 
drug-resistant clones emerged 2-3 months after initial 
exposure. Colony formation assay showed that these 
clones were highly resistant to olaparib (Fig. 1D). Lethal 
concentrations 50 (LC50) were about 450- to 600-fold 
greater than those for parental cells for olaparib. We 
Fig. 2: Generation of unphosphorylatable S6 allele (S6P-/-) in HCC1937 cells. A. The structures of endogenous S6 gene, targeting 
ssODEs. The position of the serine residures (S) and respective alanine substitutes (A) in exon 5 is indicated. B. PCR products of genomic 
DNA were digested with EcoRV. The wild-type allele (639 bp) and the doublet of the targeted allele (339 and 305 bp) are indicated. C. 
Lysates from wild-type and S6P-/- HCC1937 cells were subjected to Western blot analysis using indicated antibodies. D. S6P-/- HCC1937 
cells are sensitive to the PARP inhibitor. Colony formation assay was performed after 1 day or 2 weeks 10 nM olaparib treatment in 
indicated cell types (n=3, mean±SEM of colonies formed relative to DMSO-treated cells). The cells were first selected for the resistance to 
olaparib (2 weeks treatment) and after that plated for the colony formation assay.
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measured mTOR and S6 protein levels by Western blot. S6 
phosphorylation and its upstream kinase mTORC1 greatly 
increased in all olaparib resistant clones, whereas the total 
overall protein levels of S6 and mTORC2 were similar in 
parental cells and resistant clones (Fig. 1E), indicating that 
the mTORC1-S6 phosphorylation pathway is involved in 
PARP inhibitor resistance. To investigate drug efflux as 
a mechanism of PARP inhibitor resistance, we examined 
cellular poly(ADP-ribose)(PAR) levels to determine the 
ability of olaparib to inhibit the PARP enzyme. Western 
analysis showed that olaparib reduced the levels of PAR 
to a similar degree in HCC1937 parental cells and in 
the resistant clones (Supplemental Fig. 2). These results 
suggest that altered drug efflux does not directly contribute 
to PARP inhibitor resistance. 
S6P-/- HCC1937 cells are sensitive to the PARP 
inhibitor
To investigate the role of S6 phosphorylation 
in PARP inhibitor resistance, we generated 
unphosphorylatable S6 knock-in HCC1937 cells. A recent 
report described a high-frequency genome editing method 
based on the directional HR mechanism in somatic cells 
that utilized ssDNA oligonucleotides (ssODNs) with 
zinc-finger nucleases (ZFN) [24]. Using this method, we 
replaced all phosphorylatable serine residues (S235, S236, 
S240, S244, and S247) with alanines in the endogenous 
S6 gene (Fig. 2A). We designed a ssODN donor to span 
the mutation site and the ZFN cleavage site as well as 
flanking homology sequence. The S6-specific ZFNs 
Fig. 3: Detection of γH2AX and RAD51 foci in S6P-
/- cells and PARP resistant cells. A. Decrease of γH2AX 
and increase of RAD51 foci in the PARP resistant HCC1937 
clone cells. Immunofluorescence images show γH2AX and 
RAD51 foci and DAPI counterstain in HCC1937 parental 
and resistant cells with 2 Gy IR-treatment for 2 h. Upper panel 
shows representative cells. Bottom panel shows the percentage 
of cells with γH2AX and RAD51 foci (n=200 counted for each 
cell type). >5 Foci/cell were counted as a positive cell. The P 
values are <0.001 between parental cells and OR clones, based 
on Student’s t test. B. Detection of γH2AX and RAD51 foci in 
S6P-/- cells. Quantitative data show the percentage of cells with 
γH2AX and RAD51 foci (n=200). The P values are <0.01 among 
S6+/+, S6P-/- and OR1 cells, based on Student’s t test.
Fig. 4: Rapamycin restores sensitivity of HCC1937 
resistant clones to the PARP inhibitor. A. Colony formation 
assay was performed in HCC1937 parental and olaparib resistant 
cells, and S6P-/- cells with or without 1 µM rapamycin and/or 
10 nM olaparib treatment (n=3, mean±SEM of colonies formed 
relative to DMSO-treated cells). B. Whole-cell lysates were 
analyzed by Western blotting with the indicated antibodies. C. 
Detection of γH2AX and RAD51 foci. Quantitative data show 
the percentage of cells with γH2AX and RAD51 foci (n=200). 
>5 Foci/cell were counted as a positive cell. The P values are 
<0.01 between treatment with and without rapamycin in S6+/+and 
OR1 cells, based on Student’s t test.
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are fusion proteins including the engineered zinc finger 
proteins that specifically bind to exon 5 of S6 genomic 
DNA, and the non-specific nuclease domain of restriction 
enzyme FokI that generates double-strand DNA cleavage, 
which also greatly stimulated HR frequency for ssODN 
donor replacement. The replacement of genomic DNA 
with ssODN-S6-130 through the cellular process of HR 
resulted in creating a knock-in S6P-/-. To enable restriction 
fragment length polymorphism (RFLP)-based detection to 
targeted clones, we also introduced an EcoRV site. After 
transfection of ssODN S6-130 and mRNA encoding the 
S6 ZFN into HCC1937 cells, 400 single-cell clones were 
Fig. 5: Combinational treatment of rapamycin with olaparib effectively suppresses BRCA1-deficient tumor growth in 
mice. A. S6P-/- HCC1937 cells-induced tumors in mice are decreased. After 9 weeks, the tumors became rigid and the volume of tumor 
((L × W2)/2) is measured (n=20 each group). The P values are <0.01 between S6+/+/OR1 and S6P-/- groups, based on Student’s t test. B. 
Combinational treatment of rapamycin with olaparib significantly suppresses tumor growth in the xenograft tumors. Tumor growth rates 
after the drug treatments are shown (S6+/+, n=19; S6P-/-, n=12; OR1, n=20). The mice bearing xenograft tumors were assigned to vehicle and 
treatment groups and mean tumor volumes at the start point (after 9 weeks implanting cells) for treatment were indistinguishable between 
the vehicle and treatment groups. C. Statistical analysis of effects of the drugs on tumor growth for mice bearing xenograft tumors (after 18 
days treatment). The P values are <0.001 between olaparib alone and rapamycin+olaparib treatment in S6+/+and OR1 groups, and between 
parental control and S6P-/- tumors with olaparib alone treatment, based on Student’s t test.
Oncotarget3380www.impactjournals.com/oncotarget
obtained and screened by RFLP assay (Fig. 2B). Four 
S6P-/- monoclonal lines were identified then verified by 
qPCR, Southern blot, Northern blot and genomic DNA 
sequencing (Supplementary Fig. 3 and data not shown). 
Western blot analysis using anti-phospho-Ser235/236 or –
Ser240/244 antibodies, did not detect any phosphorylation of 
these sites in S6 (Fig. 2C). Together these data demonstrate 
that these phosphorylatable serine residues in S6 are 
absent in S6P-/- HCC1937 cells. To determine the role 
of S6 phosphorylation in PARP inhibitor resistance, we 
cultured S6P-/- HCC1937 cells with olaparib and measured 
cell survival. Results from colony formation assays 
indicated that S6P-/- cells were highly sensitive to olaparib 
(Fig. 2D) and LC50 was about 400- to 600-fold lower than 
those for olaparib resistance clones. We conclude that S6 
phosphorylation may be responsible for PARP inhibitor 
resistance in BRCA1 deficient cells.
DNA damage response and repair in S6P-/- cells 
and PARP resistant cells
Next, we examined the DNA damage response 
by measuring the formation of nuclear foci containing 
phosphorylated histone γH2AX, a surrogate marker 
of DNA double-strand break. Immunostaining assay 
showed that γH2AX foci were readily detected in parental 
HCC1937 cells following irradiation (IR), consistent with 
the previous report [21]. In the olaparib resistant clones, 
γH2AX foci were significantly decreased, compared with 
those in the parental cells (Fig. 3A; Supplementary Fig. 4). 
Furthermore, quantitative data revealed a 2-fold increase 
in S6P-/- HCC1937 cells with H2AX foci, compared with 
S6 wild-type cells (Fig. 3B; Supplementary Fig. 5). Thus, 
these data indicate that S6 phosphorylation is involved in 
the DNA damage response. 
BRCA1-deficient cells display defective in HR 
[11;12]. Therefore, we measured RAD51 focus formation 
Fig. 6: Rapamycin treatment inhibits the pS6 expression level in the xenograft tumors in mice. A. Western blot analysis 
was performed from the xenograft tumors in mice with indicated antibodies. B. IHC analysis of pS6 and S6 in the xenograft tumors with 
or without indicated drug treatment. Original magnification × 200. Scale bar, 10 µm. C. Detection of γH2AX foci in the xenograft tumors. 
Quantitative data show the percentage of cells with γH2AX foci (n=200). >5 foci/cell were counted as a positive cell.
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after IR, a marker for HR, which is impaired in BRCA1-
deficient cells [25-27]. Wild-type, PARP resistant clone 
and S6P-/- HCC1937 cells were treated with IR and stained 
with a RAD51 antibody (Fig. 3B, Supplementary Fig. 
5). Analysis of these IR-induced RAD51 foci revealed a 
diminished response upon depletion of BRCA1, consistent 
with previous observations [25;27]. PARP resistant clones 
readily formed RAD51 foci following IR. Moreover, 
RAD51 foci could not be detected in S6P-/- HCC1937 cells. 
These data suggest that S6 phosphorylation might regulate 
the HR process.
Rapamycin restores sensitivity of HCC1937 
resistant clones to the PARP inhibitor
To further study the role of mTOR/S6 pathway 
in PARP resistance, we tested the effect of rapamycin, 
a clinically used selective inhibitor of mTORC1 and 
S6 phosphorylation. Treatment with rapamycin alone 
produced a reduction of colony formation in the similar 
level in HCC1937 S6P-/-, olaparib resistant and parental 
cells (Fig. 4A; Supplementary Fig. 6). Furthermore, these 
cells were very sensitive to combinational treatments 
of rapamycin with olaparib, and almost no clones were 
formed, suggesting that rapamycin could overcome 
olaparib resistance and S6 phosphorylation may be 
associated with it. Western blot analysis showed that 
rapamycin treatment suppressed S6 phosphorylation in 
olaparib resistant cells as well as in HCC1937 parental 
cells (Fig. 4B), supporting a role for S6 phosphorylation 
in PARP inhibitor resistance. As expected, rapamycin 
treatment significantly increased γH2AX foci and 
decreased RAD51 foci in the olaparib resistant clone (Fig. 
4C). Taken together, these data indicate that rapamycin 
may restore BRCA1 deficient cell sensitivity to olaparib 
through inhibition of S6 phosphorylation.
Combined rapamycin and PARP inhibitor 
treatment effectively suppresses BRCA1-deficient 
tumor growth in mice
The colony formation assay showed reduced cell 
viabilities in S6P-/- HCC1937 cells compared with parental 
control cells (Fig. 4A), suggesting that S6 phosphorylation 
may be involved in tumorigenesis. Therefore, HCC1937 
S6P-/-, olaparib resistant and parental cells were implanted 
into SCID mice and tumor formation was monitored 
for 9 weeks. Implantation of control parental HCC1937 
cells resulted in tumor formation in 19 of 20 mice (Fig. 
5A). Removal of the S6 phosphorylations was sufficient 
to suppress tumor development and only 12 of 20 mice 
generated tumors. All olaparib resistant cells generated 
tumors (n=20). In addition, these resistant cells also 
resulted in larger tumors compared with those from 
parental control cells (Fig. 5 and data not shown). 
We tested the effects of rapamycin and olaparib on 
Brca1-deficient tumors in mice and found that olaparib 
significantly inhibited S6-/- tumor growth. Rapamycin 
treatment inhibited tumor growth from all transplanted 
cell lines including olaparib resistant cells (Figs. 5BC), 
suggesting that rapamycin may have better therapeutic 
effects on olaparib resistant tumors and the tumors with 
high expressing level of S6 phosphorylation. Consistent 
with this hypothesis, combination treatments of rapamycin 
with olaparib had a more inhibitory effect for olaparib 
resistant cell-induced tumors as well as parental cell-
induced tumors (Figs. 5BC). Analyses of tumor lysates 
by Western blot and IHC assays indicated that rapamycin 
greatly reduced the levels of S6 phosphorylation (Figs. 
6AB), consistent with rapamycin inhibition of the mTOR 
signaling. Consistent with in vitro data, rapamycin 
treatment significantly increased γH2AX foci in the 
olaparib resistant cell-induced tumors and parental control 
cell-induced tumors (Fig. 6C). 
DISCUSSION
Previously we found that the BRCA1-AKT1 
pathway contributes to tumorigenesis and that the AKT1/
mTOR is a novel therapeutic target for BRCA1-deficient 
cancers [21-23]. Here, we provide evidence that, under 
PARP inhibitor selection pressure, phosphorylation of 
ribosomal protein S6 is dramatically increased. Using both 
rapamycin and a S6 mutant deficient for phosphorylation, 
we have shown that S6 phosphorylation is an important 
mediator of the PARP inhibitor resistance. We have 
found a synergy between rapamycin and olaparib for 
the treatment of BRCA1-mutant and olaparib resistant 
tumors. Importantly, S6 phosphorylation attenuates 
DNA damage and promotes RAD51 loading onto 
DNA following DNA damage. Both rapamycin and the 
phosphorylation deficient S6 mutant enhance γH2AX 
focus formation without altering PAR activity, suggesting 
increased DNA damage when S6 phosphorylation is 
inhibited in the context of BRCA1 mutation. In vivo 
γH2AX foci in tumors were increased when mice were 
treated with rapamycin during the period of response, 
supporting a progressive accumulation of unrepaired DNA 
DSBs. Consistent with this notion, a recent report has 
shown that S6 phosphorylation attenuates DNA damage 
and tumor suppression in pancreatic cancer [28]. Of 
particular interest is our observation that inhibition of S6 
phosphorylation greatly reduces RAD51 focus formation 
in the PARP resistant cells. These results suggest that S6 
phosphorylation is required for recruitment of RAD51 
into DNA damage sites. Because BRCA1 is a key factor 
recruiting RAD51 to DNA damage sites, it is possible 
that S6 phosphorylation becomes more critical for this 
recruitment in BRCA1 deficient cells. Previous reports 
have shown that the PTEN-PI3K pathway contributes 
to DNA DSB accumulation [29-31], possible through 
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regulation of PARP activation. It would not contribute 
to the reliance on PARP activity for DNA damage repair 
because we do not observe alteration of PARP activity in 
our model. In future studies, additional experiments will 
be needed to understand the molecular mechanism of these 
factors in DNA repair processes. 
Recent reports show that 53BP1 loss rescues 
BRCA1 deficiency and is associated with triple-negative 
and Brca1-mutated breast cancer [32;33]. However, 
other reports indicate that 53BP1 depletion only partly 
contributes to PARP inhibitor resistance [34] and confers 
only a slight degree of resistance [15;35]. 53BP1 inhibits 
HR in Brca1-deficient cells by blocking resection of 
DNA breaks. We have previously shown that the AKT 
pathway is associated with HR in BRCA1-deficient cells 
[21]—this is somewhat similar to the ability of 53BP1 
loss rescuing HR in BRCA1-deficient cells. We did not 
observe 53BP1 changes during olaparib treatment in 
our model (Supplementary Fig. 7), suggesting that S6 
phosphorylation and 53BP1 independently regulate HR in 
BRCA1-deficient cells resistant to PARP inhibitor. 53BP1 
and BRCA1 may regulate the choice between HR and 
non-homologous end joining. One critical function for 
BRCA1 might be to remove end-joining proteins such as 
53BP1 from replication-associated breaks. Thus, BRCA1 
might regulate phosphorylated S6 and 53BP1 in different 
steps during the HR process. The molecular details of 
these proteins in the HR process need further investigation 
in the future.
One mechanism of PARP resistance is upregulation 
of drug efflux pumps [19;20]. Although we did not 
observe any change in PARP activity in resistant cells, we 
cannot rule out that S6 phosphorylation might indirectly 
contribute to PARP inhibition resistance through this 
mechanism. PARP activation induces the depletion of 
its substrate NAD+ and consecutively depletion of ATP, 
resulting in energy loss and eventually cell apoptosis. 
Previous reports have shown that S6 phosphorylation 
is a determinant of glucose homeostasis [36;37]. S6P-
/- mice have impaired glucose tolerance through insulin 
deficiency [37], leading to decreased energy production 
via glycolysis. Both glycolysis and PAR consume NAD+ 
and compete for NAD+ in the cytosol. PARP inhibition 
spares NAD+ and generates a prosurvival effect for PARP 
inhibitor resistant cells. Inhibition of S6 phosphorylation 
leads to low level of glucose supply and glycolytic 
activity, leading to cell apoptosis. Therefore, a possible 
interpretation for the synergy of S6 phosphorylation and 
PARP inhibition is that inhibition of S6 phosphorylation 
reverses the effects of PARP inhibitor resistance on cell 
survival. Consistent with this model, a recent report 
shows that PI3K inhibition can reverse response of PARP 
inhibition through enhancement of glucose uptake and 
AKT phosphorylation [31]. 
Collectively, S6 phosphorylation might play a key 
role in PARP inhibitor resistance through regulations 
of DNA damage response/the HR repair process and 
glucose metabolism. Combinational inhibitions of S6 
phosphorylation and PARP might predict to be particularly 
effective in cancers with PARP inhibitor resistance and 
HR defects, such as BRCA1-deficient breast and ovarian 
cancers. 
MATERIALS AND METHODS
Cell culture, lentivirus infection and western blot 
analysis
HCC1937, Brca1+/+ and Brca1tr/tr MEFs, SUM149, 
MCF7 and MDA-MB-232 breast cancer cells were 
cultured as described previously [21-23]. To generate 
lentiviral particles, 293 T cells were cotransfected with 
the lentiviral vectors and compatible packaging plasmids 
mixture using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA), and the lentivirus supernatant was collected 
40 h after transfection. For virus infection, cells were 
exposed to lentivirus supernatant for 24 h in the presence 
of polybrene (Sigma, St Louis, MO, USA). Protein 
extracts from cells and xenograft tumors were extracted 
to conduct western blot analysis as described previously 
[23;38-40].
Antibodies and reagents
Anti-S6 ribosomal protein antibodies S6 and pS6, 
anti-mTOR (raptor and rictor) and anti-PARP antibodies 
were from Cell Signaling Technology. Anti-β-actin 
antibody was from Sigma. The goat anti-mouse IgG-HRP, 
goat anti-rabbit IgG-HRP, goat anti-mouse IgG-biotin 
and goat anti rabbit-IgG-biotin second antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Vectastain ABC kit and DAB substrate kit were from 
Vector Laboratories. 
Knock-in of S6P-/- by zinc finger nucleases (ZFNs) 
in HCC1937 cells
CompoZr Knockout Zinc Finger Nucleases targeting 
human S6 exon 5 genomic DNA were from Sigma. S6 
ZFN-mRNAs were transfected into HCC1937 cells 
and Cel-I assay was performed to check efficiency of 
depleting S6. ssODN-S6-130 was designed to replace 
all phosphorylatable serine residues 235, 236, 240, 244, 
and 247 with alanines in the S6 gene with an EcoRV site. 
ssODN-S6-130 was synthesized and co-transfected with 
S6 ZFN-mRNAs into HCC 1937 cells. The cells were 
plated in100mm dish for single clone formation. The 400 
single cell clones were picked, cultured and screened by 
RFLP assay. Four S6P-/- clones were verified by qPCR, 
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Southern, Northern, Western blot analysis and genomic 
DNA sequence. 
Indirect immunofluorescence
Experiments were performed as described 
[39;41;42]. Briefly, for conventional immunofluorescence 
microscopy, the cells were examined with a Zeiss 
Axioskop fluorescence microscope equipped with a CCD 
camera (Ontario, NY, USA). Images were captured, 
pseudocolored and merged using IPLab image analysis 
software. At least 200 cells were analyzed for each 
experiment. The experiments were repeated at least three 
times.
Colony formation assays
Cells were plated and cultured in 60 mm dishes in 
triplicate. Cells were incubated for about 14–16 days until 
colonies were large enough to visualize. Colonies were 
observed under phase contrast microscope and viable cell 
clones were measured. All data were normalized relative 
to the control. Experiments were performed three times.
Tumor growth and treatment experiments
Animal experiments were performed according to 
institutional guidelines for animal welfare. Female NOD.
SCID/NCR mice of 6–8 weeks of age were purchased 
from NCI-Frederick Animal Production Program 
(Frederick, MA, USA). In all, 2 × 106 HCC1937 S6P-/-, 
olaparib resistant and parental cells in 0.1 ml PBS were 
mixed with equal volume of matrigel. The cell mixture 
was implanted into mouse breast fat pad. After 9 weeks, 
the tumors became rigid and the volume of tumor ((L × 
W2)/2) is measured in range of 180–250 mm3. The mice 
were assigned to vehicle and treatment groups and mean 
tumor volumes at the start point for treatment were 
indistinguishable between the vehicle and treatment 
groups. Rapamycin was injected at 0.3 mg/kg diluted in 
100 μl of vehicle on the first treatment and then at 0.15 mg/
kg every other day for 18 days. Olaparib was used at 50 
mg/kg every other day for 18 days. Control mice received 
100 μl of vehicle only. At the end of treatment, the mice 
were killed and the tumors were excised and processed to 
paraffin section and protein extraction.
IHC assay
IHC was performed by using S6 and pS6 antibodies. 
Paraffin slides were deparaffinized and rehydrated by 
sequential incubations in xylene, 100% ethanol and 95% 
ethanol. Endogenous peroxidases were quenched for 
20 min with 3% H2O2 at room temperature. An antigen 
retrieval step was performed by placing slides in preheated 
sodium citrate buffer (10 mM, pH 6.0) and heated for 
10 min in a pressure cooker. The slides were allowed to 
cool to room temperature. Slides were blocked with 5% 
of goat serum in Tris buffered saline (TBS) buffer for 
60 min at room temperature. The diluted primary antibody 
was then added and incubated in a moist chamber at 4 °C 
overnight. Biotinylated secondary antibody was added for 
30 min at room temperature. To detect primary antibody 
binding, ABC and DAB kits were applied according to 
the manufacturer instruction (Vector Laboratories). After 
mounting, the slides were observed under microscope and 
pictures were taken.
ACKNOWLEDGMENTS
We thank Buck Rogers and Wilbur Song for 
proofreading this manuscript. This work is supported in 
part by grants from the Natural Science Foundation of 
China (No. 81228017), the Concern Foundation (QY) and 
NIH CA129440 (QY). 
Author Contributions
QY generated the hypotheses, designed experiments 
and analyzed data. FZ, CKS, and TX performed 
experiments and generated data. TKP, YH, QMC and 
MCTH provided reagents and analyzed data. QY and TKP 
wrote the manuscript.
REFERENCES
1.  Thompson,M.E., Jensen,R.A., Obermiller,P.S., Page,D.L., 
and Holt,J.T. (1995) Decreased expression of BRCA1 
accelerates growth and is often present during sporadic 
breast cancer progression. Nat.Genet., 9, 444-450.
2.  Narod,S.A. and Foulkes,W.D. (2004) BRCA1 and BRCA2: 
1994 and beyond. Nat.Rev.Cancer, 4, 665-676.
3.  Yu,X., Chini,C.C., He,M., Mer,G., and Chen,J. (2003) 
The BRCT domain is a phospho-protein binding domain. 
Science, 302, 639-642.
4.  Manke,I.A., Lowery,D.M., Nguyen,A., and Yaffe,M.B. 
(2003) BRCT repeats as phosphopeptide-binding modules 
involved in protein targeting. Science, 302, 636-639.
5.  Ludwig,T., Fisher,P., Ganesan,S., and Efstratiadis,A. 
(2001) Tumorigenesis in mice carrying a truncating Brca1 
mutation. Genes Dev., 15, 1188-1193.
6.  Williams,R.S., Lee,M.S., Hau,D.D., and Glover,J.N. (2004) 
Structural basis of phosphopeptide recognition by the 
BRCT domain of BRCA1. Nat.Struct.Mol.Biol., 11, 519-
525.
7.  Zhang,J. and Powell,S.N. (2005) The role of the BRCA1 
tumor suppressor in DNA double-strand break repair. Mol.
Cancer Res., 3, 531-539.
Oncotarget3384www.impactjournals.com/oncotarget
8.  Farmer,H., McCabe,N., Lord,C.J., Tutt,A.N., Johnson,D.A., 
Richardson,T.B., Santarosa,M., Dillon,K.J., Hickson,I., 
Knights,C., Martin,N.M., Jackson,S.P., Smith,G.C., and 
Ashworth,A. (2005) Targeting the DNA repair defect in 
BRCA mutant cells as a therapeutic strategy. Nature, 434, 
917-921.
9.  Thompson,L.H. and Schild,D. (2001) Homologous 
recombinational repair of DNA ensures mammalian 
chromosome stability. Mutat.Res., 477, 131-153.
10.  Kennedy,R.D., Quinn,J.E., Mullan,P.B., Johnston,P.G., 
and Harkin,D.P. (2004) The role of BRCA1 in the cellular 
response to chemotherapy. J.Natl.Cancer Inst., 96, 1659-
1668.
11.  Moynahan,M.E., Chiu,J.W., Koller,B.H., and Jasin,M. 
(1999) Brca1 controls homology-directed DNA repair. Mol.
Cell, 4, 511-518.
12.  Scully,R., Ganesan,S., Vlasakova,K., Chen,J., 
Socolovsky,M., and Livingston,D.M. (1999) Genetic 
analysis of BRCA1 function in a defined tumor cell line. 
Mol.Cell, 4, 1093-1099.
13.  Fong,P.C., Boss,D.S., Yap,T.A., Tutt,A., Wu,P., Mergui-
Roelvink,M., Mortimer,P., Swaisland,H., Lau,A., 
O’Connor,M.J., Ashworth,A., Carmichael,J., Kaye,S.B., 
Schellens,J.H., and de Bono,J.S. (2009) Inhibition of 
poly(ADP-ribose) polymerase in tumors from BRCA 
mutation carriers. N.Engl.J.Med., 361, 123-134.
14.  Fong,P.C., Yap,T.A., Boss,D.S., Carden,C.P., Mergui-
Roelvink,M., Gourley,C., De,G.J., Lubinski,J., Shanley,S., 
Messiou,C., A’Hern,R., Tutt,A., Ashworth,A., Stone,J., 
Carmichael,J., Schellens,J.H., de Bono,J.S., and Kaye,S.B. 
(2010) Poly(ADP)-ribose polymerase inhibition: frequent 
durable responses in BRCA carrier ovarian cancer 
correlating with platinum-free interval. J.Clin.Oncol., %20
;28, 2512-2519.
15.  Johnson,N., Johnson,S.F., Yao,W., Li,Y.C., Choi,Y.E., 
Bernhardy,A.J., Wang,Y., Capelletti,M., Sarosiek,K.A., 
Moreau,L.A., Chowdhury,D., Wickramanayake,A., 
Harrell,M.I., Liu,J.F., D’Andrea,A.D., Miron,A., 
Swisher,E.M., and Shapiro,G.I. (2013) Stabilization 
of mutant BRCA1 protein confers PARP inhibitor and 
platinum resistance. Proc.Natl.Acad.Sci.U.S.A., 110, 
17041-17046.
16.  Norquist,B., Wurz,K.A., Pennil,C.C., Garcia,R., Gross,J., 
Sakai,W., Karlan,B.Y., Taniguchi,T., and Swisher,E.M. 
(2011) Secondary somatic mutations restoring BRCA1/2 
predict chemotherapy resistance in hereditary ovarian 
carcinomas. J.Clin.Oncol., 29, 3008-3015.
17.  Dhillon,K.K., Swisher,E.M., and Taniguchi,T. (2011) 
Secondary mutations of BRCA1/2 and drug resistance. 
Cancer Sci., 102, 663-669.
18.  Swisher,E.M., Sakai,W., Karlan,B.Y., Wurz,K., Urban,N., 
and Taniguchi,T. (2008) Secondary BRCA1 mutations 
in BRCA1-mutated ovarian carcinomas with platinum 
resistance. Cancer Res., 68, 2581-2586.
19.  Bouwman,P. and Jonkers,J. (2014) Molecular Pathways: 
How Can BRCA-Mutated Tumors Become Resistant to 
PARP Inhibitors? Clin.Cancer Res., 20, 540-547.
20.  Bouwman,P. and Jonkers,J. (2012) The effects of 
deregulated DNA damage signalling on cancer 
chemotherapy response and resistance. Nat.Rev.Cancer., 
12, 587-598.
21.  Jia,Y., Song,W., Zhang,F., Yan,J., and Yang,Q. (2013) 
Akt1 inhibits homologous recombination in Brca1-deficient 
cells by blocking the Chk1-Rad51 pathway. Oncogene., 32, 
1943-1949.
22.  Xiang,T., Ohashi,A., Huang,Y., Pandita,T.K., Ludwig,T., 
Powell,S.N., and Yang,Q. (2008) Negative Regulation of 
AKT Activation by BRCA1. Cancer Res., 68, 10040-10044.
23.  Xiang,T., Jia,Y., Sherris,D., Li,S., Wang,H., Lu,D., and 
Yang,Q. (2011) Targeting the Akt/mTOR pathway in 
Brca1-deficient cancers. Oncogene.
24.  Chen,F., Pruett-Miller,S.M., Huang,Y., Gjoka,M., Duda,K., 
Taunton,J., Collingwood,T.N., Frodin,M., and Davis,G.D. 
(2011) High-frequency genome editing using ssDNA 
oligonucleotides with zinc-finger nucleases. Nat.Methods., 
8, 753-755.
25.  Chen,J.J., Silver,D., Cantor,S., Livingston,D.M., and 
Scully,R. (1999) BRCA1, BRCA2, and Rad51 operate in a 
common DNA damage response pathway. Cancer Res., 59, 
1752s-1756s.
26.  Scully,R., Chen,J., Plug,A., Xiao,Y., Weaver,D., 
Feunteun,J., Ashley,T., and Livingston,D.M. (1997) 
Association of BRCA1 with Rad51 in mitotic and meiotic 
cells. Cell, 88, 265-275.
27.  Bhattacharyya,A., Ear,U.S., Koller,B.H., 
Weichselbaum,R.R., and Bishop,D.K. (2000) The 
breast cancer susceptibility gene BRCA1 is required for 
subnuclear assembly of Rad51 and survival following 
treatment with the DNA cross-linking agent cisplatin. J.Biol 
Chem., 275, 23899-23903.
28.  Khalaileh,A., Dreazen,A., Khatib,A., Apel,R., Swisa,A., 
Kidess-Bassir,N., Maitra,A., Meyuhas,O., Dor,Y., and 
Zamir,G. (2013) Phosphorylation of ribosomal protein S6 
attenuates DNA damage and tumor suppression during 
development of pancreatic cancer. Cancer Res., 73, 1811-
1820.
29.  Yin,Y. and Shen,W.H. (2008) PTEN: a new guardian of the 
genome. Oncogene., 27, 5443-5453.
30.  Shen,W.H., Balajee,A.S., Wang,J., Wu,H., Eng,C., 
Pandolfi,P.P., and Yin,Y. (2007) Essential role for nuclear 
PTEN in maintaining chromosomal integrity. Cell., 128, 
157-170.
31.  Juvekar,A., Burga,L.N., Hu,H., Lunsford,E.P., 
Ibrahim,Y.H., Balmana,J., Rajendran,A., Papa,A., 
Spencer,K., Lyssiotis,C.A., Nardella,C., Pandolfi,P.P., 
Baselga,J., Scully,R., Asara,J.M., Cantley,L.C., and 
Wulf,G.M. (2012) Combining a PI3K inhibitor with a 
PARP inhibitor provides an effective therapy for BRCA1-
Oncotarget3385www.impactjournals.com/oncotarget
related breast cancer. Cancer Discov., 2, 1048-1063.
32.  Bunting,S.F., Callen,E., Wong,N., Chen,H.T., Polato,F., 
Gunn,A., Bothmer,A., Feldhahn,N., Fernandez-
Capetillo,O., Cao,L., Xu,X., Deng,C.X., Finkel,T., 
Nussenzweig,M., Stark,J.M., and Nussenzweig,A. (2010) 
53BP1 inhibits homologous recombination in Brca1-
deficient cells by blocking resection of DNA breaks. Cell, 
141, 243-254.
33.  Bouwman,P., Aly,A., Escandell,J.M., Pieterse,M., 
Bartkova,J., van der,G.H., Hiddingh,S., Thanasoula,M., 
KulKarni,A., Yang,Q., Haffty,B.G., Tommiska,J., 
Blomqvist,C., Drapkin,R., Adams,D.J., Nevanlinna,H., 
Bartek,J., Tarsounas,M., Ganesan,S., and Jonkers,J. (2010) 
53BP1 loss rescues BRCA1 deficiency and is associated 
with triple-negative and BRCA-mutated breast cancers. Nat.
Struct.Mol Biol, 17, 688-695.
34.  Jaspers,J.E., Kersbergen,A., Boon,U., Sol,W., van,D.L., 
Zander,S.A., Drost,R., Wientjens,E., Ji,J., Aly,A., 
Doroshow,J.H., Cranston,A., Martin,N.M., Lau,A., 
O’Connor,M.J., Ganesan,S., Borst,P., Jonkers,J., and 
Rottenberg,S. (2013) Loss of 53BP1 causes PARP inhibitor 
resistance in Brca1-mutated mouse mammary tumors. 
Cancer Discov., 3, 68-81.
35.  Oplustilova,L., Wolanin,K., Mistrik,M., Korinkova,G., 
Simkova,D., Bouchal,J., Lenobel,R., Bartkova,J., Lau,A., 
O’Connor,M.J., Lukas,J., and Bartek,J. (2012) Evaluation 
of candidate biomarkers to predict cancer cell sensitivity or 
resistance to PARP-1 inhibitor treatment. Cell Cycle., 11, 
3837-3850.
36.  Chauvin,C., Koka,V., Nouschi,A., Mieulet,V., Hoareau-
Aveilla,C., Dreazen,A., Cagnard,N., Carpentier,W., 
Kiss,T., Meyuhas,O., and Pende,M. (2014) Ribosomal 
protein S6 kinase activity controls the ribosome biogenesis 
transcriptional program. Oncogene., 33, 474-483.
37.  Ruvinsky,I., Katz,M., Dreazen,A., Gielchinsky,Y., 
Saada,A., Freedman,N., Mishani,E., Zimmerman,G., 
Kasir,J., and Meyuhas,O. (2009) Mice deficient in 
ribosomal protein S6 phosphorylation suffer from muscle 
weakness that reflects a growth defect and energy deficit. 
PLoS.One., %19;4, e5618.
38.  Yang,Q., Zheng,Y.L., and Harris,C.C. (2005) POT1 and 
TRF2 cooperate to maintain telomeric integrity. Mol.Cell 
Biol., 25, 1070-1080.
39.  Zeng,S., Xiang,T., Pandita,T.K., Gonzalez-Suarez,I., 
Gonzalo,S., Harris,C.C., and Yang,Q. (2009) Telomere 
recombination requires the MUS81 endonuclease. Nat.Cell 
Biol., 11, 616-623.
40.  Yang,Q., Zhang,R., Horikawa,I., Fujita,K., Afshar,Y., 
Kokko,A., Laiho,P., Aaltonen,L.A., and Harris,C.C. (2007) 
Functional diversity of human protection of telomeres 1 
isoforms in telomere protection and cellular senescence. 
Cancer Res., 67, 11677-11686.
41.  Yang,Q., Zhang,R., Wang,X.W., Linke,S.P., Sengupta,S., 
Hickson,I.D., Pedrazzi,G., Perrera,C., Stagljar,I., 
Littman,S.J., Modrich,P., and Harris,C.C. (2004) The 
mismatch DNA repair heterodimer, hMSH2/6, regulates 
BLM helicase. Oncogene, 23, 3749-3756.
42.  Zeng,S. and Yang,Q. (2009) The MUS81 endonuclease 
is essential for telomerase negative cell proliferation. Cell 
Cycle, 8, 2157-2160.
